Elutia

ELUT

----

Current ValuationThe current P/E ratio is 0.70, within the reasonable range, cheaper than 51.15% of the time in the past 1 years, and the industry ranks 8/604, the industry Median -2.12.

0.704xP/E

Stock price$0.82Earnings per share$1.17

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.18x	68.61%	$22.86B
GRFSUSGRIFOLS SA	9.78x	42.44%	$5.13B
ACADUSAcadia Pharma	8.96x	73.57%	$3.41B
ADMAUSAdma Biologics	13.73x	35.42%	$2.32B
AUPHUSAurinia Pharma	7.05x	54.40%	$2.22B
PURRUSHyperliquid Strategies	8.58x	67.60%	$2.20B
LKFTUSLakefront Biotherapeutics	2.79x	86.19%	$1.93B
ANABUSAnaptysbio	5.24x	1,003.56%	$1.37B
VORUSVor BioPharma	1.88x	89.77%	$1.18B
MGTXUSMeiraGTx	13.00x	122.03%	$1.03B
RIGLUSRigel Pharma	2.85x	83.91%	$916.81M
BVNRYUSBavarian Nordic A/S	3.72x	--	$891.83M
ABUSUSArbutus Pharma	5.43x	533.09%	$831.09M
IRWDUSIronwood Pharma	4.86x	715.55%	$631.22M
AGENUSAgenus	3.76x	--	$345.31M
CUVLUSClinuvel Pharmaceuticals	12.30x	--	$281.89M
QTTBUSQ32 Bio	7.35x	162.67%	$248.28M
PLXUSProtalix Biotherap	11.82x	400.00%	$223.99M
CGENUSCompugen	5.73x	173.68%	$201.76M
VXRTUSVaxart	2.74x	328.57%	$105.65M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.